Pellerino et al. (Pellerino et al., 2022) demonstrated that HER2-positive breast cancer patients with leptomeningeal metastases had a 70% probability of receiving a neurological benefit after treatment with neratinib plus capecitabine. This evidence concerns the gene ERBB2 and breast carcinoma.